Filtered By:
Specialty: Cardiology
Condition: Cardiogenic Shock
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 235 results found since Jan 2013.
No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial
CONCLUSION: In patients presenting with CS treated with milrinone or dobutamine, no differences in clinical outcomes were observed between males and females.PMID:35725945 | DOI:10.1016/j.jjcc.2022.06.001
Source: Journal of Cardiology - June 21, 2022 Category: Cardiology Authors: Graeme Prosperi-Porta Pouya Motazedian Pietro Di Santo Richard G Jung Simon Parlow Omar Abdel-Razek Trevor Simard Jordan Hutson Nikita Malhotra Angel Fu F Daniel Ramirez Michael Froeschl Rebecca Mathew Benjamin Hibbert CAPITAL DOREMI investigators Source Type: research
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients
CONCLUSION: In this study level meta-analysis, SMuRF-less ACS patients demonstrate higher mortality compared with patients with at least one traditional atherosclerotic risk factor. Underuse of guideline-directed medical therapy amongst SMuRF-less patients is concerning. Unraveling novel risk factors amongst SMuRF-less individuals is the next important step.SUMMARY: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes mellitus, hyperlipidemia, hypertension, and smoking, are often used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-le...
Source: Atherosclerosis - September 30, 2022 Category: Cardiology Authors: Gwyneth Kong Yip Han Chin Bryan Chong Rachel Sze Jen Goh Oliver Zi Hern Lim Cheng Han Ng Mark Muthiah Roger Foo Stephen T Vernon Poay Huan Loh Mark Y Chan Nicholas W S Chew Gemma A Figtree Source Type: research
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial
Conclusions: Immediate implementation of VA-ECMO in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy that permitted downstream use of VA-ECMO in case of worsening hemodynamic status. Clinical Trial Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT02301819.PMID:36335478 | DOI:10.1161/CIRCULATIONAHA.122.062949
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Petr Ostadal Richard Rokyta Jiri Karasek Andreas Kruger Dagmar Vondrakova Marek Janotka Jan Naar Jana Smalcova Marketa Hubatova Milan Hromadka Stefan Volovar Miroslava Seyfrydova Jiri Jarkovsky Michal Svoboda Ales Linhart Jan Belohlavek ECMO-CS Investigat Source Type: research
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
AbstractCardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes areTET2,DNMT3A,ASXL1 andJAK2. By the age of 70, at least 20 –50% of all individuals carry a CH clone, conveying a striking clinical impact by increasing all-cause mortality by 40%. This is due predominantly to a nearly two-fold increase of cardiovascular risk, but also to ...
Source: Basic Research in Cardiology - November 10, 2022 Category: Cardiology Source Type: research
Short-Term Outcomes of Impella Support in Japanese Patients With Cardiogenic Shock Due to Acute Myocardial Infarction - Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD)
CONCLUSIONS: AMICS treatment with Impella showed favorable 30-day survival and safety profiles. The survival rate of patients treated with Impella alone was particularly high. Further studies are needed to improve outcomes of patients with ECPELLA support.PMID:36682787 | DOI:10.1253/circj.CJ-22-0476
Source: Circulation Journal - January 22, 2023 Category: Cardiology Authors: Yuki Ikeda Junya Ako Koichi Toda Atsushi Hirayama Koichiro Kinugawa Yoshio Kobayashi Minoru Ono Takashi Nishimura Naoki Sato Takahiro Shindo Morimasa Takayama Satoshi Yasukochi Akira Shiose Yoshiki Sawa J-PVAD Investigators Source Type: research
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
AbstractCardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes areTET2,DNMT3A,ASXL1 andJAK2. By the age of 70, at least 20 –50% of all individuals carry a CH clone, conveying a striking clinical impact by increasing all-cause mortality by 40%. This is due predominantly to a nearly two-fold increase of cardiovascular risk, but also to ...
Source: Basic Research in Cardiology - November 10, 2022 Category: Cardiology Source Type: research
Rescue aortic valvuloplasty for severe aortic stenosis is simple and effective in severely hemodynamically compromised patients presenting to centers without on-site heart surgery or TAVI facilities
AbstractManagement of high-risk patients with severe aortic stenosis (AS) is a challenging issue. The prognosis of patients with AS presenting with therapy-refractory pulmonary edema (RPE) or cardiogenic shock (CS) remains poor. The purpose of this study was to assess the 30-day mortality of rescue percutaneous balloon aortic valvuloplasty (PBAV) in AS patients presenting with RPE or CS in a community-based hospital without on- site heart surgery. From January 2016 to February 2019, we identified consecutively admitted patients with CS or RPE related to severe AS who underwent emergent PBAV. The primary end...
Source: Heart and Vessels - February 13, 2023 Category: Cardiology Source Type: research
Predictive Value of CHA2DS2-VASc Score in Patients with Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction
CONCLUSION: Our current study showed that the CHA2DS2-VASc risk score has an effective discriminating power in determining the contrast-induced nephropathy development and a score ≥2 defines the group at risk in patients presenting with ST-elevation myocardial infarction and underwent primary percutaneous coronary intervention. Moreover, contrast-induced nephropathy development is associated with longer coronary care unit stay and major adverse cardiac events (in-hospital decompensated heart failure, cardiogenic shock, cardiac arrest, and mortality).PMID:36916809 | DOI:10.5543/tkda.2022.46994
Source: Turk Kardiyoloji Dernegi arsivi - March 14, 2023 Category: Cardiology Authors: Esra D önmez Sevgi Özcan Orhan İnce İrfan Şahin Ertu ğrul Okuyan Source Type: research
Clonal Hematopoiesis and the Heart: a Toxic Relationship
Curr Oncol Rep. 2023 Mar 15. doi: 10.1007/s11912-023-01398-1. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Clonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.RECENT FINDINGS: A combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atheroscle...
Source: Atherosclerosis - March 15, 2023 Category: Cardiology Authors: Jeffrey L Jensen Saumya Easaw Travis Anderson Yash Varma Jiandong Zhang Brian C Jensen Catherine C Coombs Source Type: research
Predictive Value of CHA2DS2-VASc Score in Patients with Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction
CONCLUSION: Our current study showed that the CHA2DS2-VASc risk score has an effective discriminating power in determining the contrast-induced nephropathy development and a score ≥2 defines the group at risk in patients presenting with ST-elevation myocardial infarction and underwent primary percutaneous coronary intervention. Moreover, contrast-induced nephropathy development is associated with longer coronary care unit stay and major adverse cardiac events (in-hospital decompensated heart failure, cardiogenic shock, cardiac arrest, and mortality).PMID:36916809 | DOI:10.5543/tkda.2022.46994
Source: Turk Kardiyoloji Dernegi arsivi - March 14, 2023 Category: Cardiology Authors: Esra D önmez Sevgi Özcan Orhan İnce İrfan Şahin Ertu ğrul Okuyan Source Type: research
